We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97
Webinar

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97
Webinar

Fragment-Based Drug Discovery of Cofactor-Specific Inhibitors for p97

The AAA-ATPase p97 is an essential protein involved in numerous cellular processes and plays a key role in multiple aspects of protein homeostasis. Its functional diversity is mediated through the interaction with many distinct cofactors. Due to its significant role in regulating a variety of physiological responses, p97 has emerged as a potential therapeutic target. In this webinar, Sebastian Bothe from the University of W├╝rzburg will present a combined approach that exploits computer-based methods, including virtual screening of molecular databases and biochemical/biophysical techniques.

Accelerate your research with a field-upgradeable, label-free biomolecule analysis platform. Octet® systems have become indispensable analytical instruments enabling a broad range of application and workflow requirements. In his presentation, Dr Helge Schnerr, Global Campaign Manager at Sartorius will provide an overview of label-free biolayer interferometry (BLI) and its benefits.

Attend this webinar to learn more about: 

  • How to select potential candidates
  • The use of biolayer interferometry (BLI) for fragment screenings
  • Developing label-free assays for small molecule characterization
  • Optimizing the measurement of small molecule inhibitors
Speakers
Sebastian Bothe
Sebastian Bothe
PostDoc, Department of Biochemistry, University of Wuerzburg, Germany
Dr Helge Schnerr
Dr Helge Schnerr
Global Campaign Manager, Sartorius
Advertisement